At a glance
| Chemical family | Glycol ether (2-phenoxyethanol; ethylene glycol monophenyl ether); broad-spectrum cosmetic preservative effective against bacteria and yeast; the dominant paraben replacement in modern personal care formulations |
| CAS number | 122-99-6 |
| Classification | Not formally evaluated by IARC; EU Cosmetics Regulation 1223/2009 Annex V permits at up to 1.0% in finished products; EU SCCS 2016 opinion confirmed 1.0% as safe; French ANSM 2012 recommended against phenoxyethanol in leave-on products for children under 3 (more restrictive than EU SCCS consensus); US FDA permits under broader cosmetic regulation framework; FDA May 23, 2008 warning letter on Mommy's Bliss Nipple Cream specifically addressed breastfeeding infant oral exposure; CIR Safety Assessment supports current use levels |
| Where you encounter it | The most common paraben replacement — appears in nearly all "paraben-free" cosmetic formulations as the substitute preservative; lotions, sunscreens, shampoos, conditioners, body washes, makeup, perfumes; baby wipes (a particularly studied use-case); pharmaceutical formulations including some vaccines (as preservative); household cleaners |
| Sleep micro environment relevance | Same indirect pathway as the parabens — leave-on phenoxyethanol-containing products transfer to bedding overnight via skin contact and sweat. Cumulative across the multiple personal-care products in a typical routine. The paraben-to-phenoxyethanol substitution shifts the chemistry of bedding deposition but doesn't eliminate the deposition |
| Activated carbon capture | Limited applicability for product-residue dermal exposure; activated carbon as designed for VOC capture is not the relevant technology for cosmetic dermal exposure. The primary intervention is product-choice level. Inferred from established cosmetic exposure pathways |
What it is
Phenoxyethanol — CAS 122-99-6, chemical name 2-phenoxyethanol (also called ethylene glycol monophenyl ether) — is a glycol ether: a phenol group connected to a two-carbon hydroxyalkyl chain through an ether oxygen. The compound is a colorless to pale yellow liquid at room temperature with a faint rose-like odor at concentrated levels (though essentially odorless at cosmetic use concentrations). Phenoxyethanol is produced industrially by reaction of phenol with ethylene oxide; the same compound also occurs naturally at trace concentrations in some plants including green tea and chicory, though the cosmetic-use volume is overwhelmingly synthetic.
The mechanism of antimicrobial preservation involves disruption of bacterial and yeast cell membrane integrity. Phenoxyethanol is effective against a broad spectrum of organisms including Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, and various yeasts and molds. It is often combined with other preservatives (ethylhexylglycerin, caprylyl glycol, sorbic acid) for broad-spectrum activity, particularly in "natural" cosmetic product lines that avoid parabens and formaldehyde-releasers.
The compound is moderately lipophilic and is absorbed through skin, though absorption rates are well-characterized at typical cosmetic concentrations. Absorbed phenoxyethanol is metabolized primarily by oxidation to phenoxyacetic acid (the major urinary metabolite) and excreted within hours to a day. The short biological half-life means body burden tracks closely with current exposure and stopping exposure produces rapid reduction in biomarker levels — parallel to the paraben and triclosan kinetics rather than the slow accumulation of lead, cadmium, or persistent organic pollutants.
Where you encounter it
The most common paraben replacement
Phenoxyethanol is the dominant paraben replacement preservative in modern cosmetic formulations. When the parabens-free consumer pressure cycle drove industry reformulation through the 2000s and 2010s, the most common destination chemistry was phenoxyethanol — either alone at the 1.0% EU regulatory limit or combined with ethylhexylglycerin (a synergist that improves antimicrobial efficacy at lower phenoxyethanol concentrations). Reading a "paraben-free" cosmetic ingredient label, phenoxyethanol typically appears in the preservation slot.
From leave-on lotions, sunscreens, and skin products
Body lotions, hand creams, face creams, sunscreens, deodorants, and similar leave-on products commonly contain phenoxyethanol as the primary or secondary preservative. The all-over body application produces measurable cumulative dermal exposure. Sunscreen use during summer months and the prolonged daily-routine duration drive the largest single contribution to total daily phenoxyethanol exposure in typical adult populations.
From shampoos, conditioners, and rinse-off products
Most major shampoo, conditioner, body wash, and hand soap brands use phenoxyethanol as standard preservation chemistry, often combined with other preservatives. The rinse-off nature reduces per-application exposure compared to leave-on products, but use frequency makes the cumulative dose meaningful.
From baby wipes — the particularly studied use case
Baby wipes have been a focal point for phenoxyethanol exposure assessment, partly because of the infant-skin permeability and partly because the application area (the nappy region) has higher skin permeability than adult skin in general. The French ANSM 2012 evaluation specifically considered baby wipes and similar leave-on infant products in its recommendation against phenoxyethanol in products for children under 3. EU SCCS subsequent review confirmed the 1.0% concentration limit for general population including infants — the disagreement between the French national position and the EU consensus position remains unresolved.
From the FDA Mommy's Bliss warning context
The most-cited single regulatory event for phenoxyethanol is the US FDA's May 23, 2008 warning letter against Mommy's Bliss Nipple Cream, manufactured by MOM Enterprises. Regulatory The product contained phenoxyethanol (along with chlorphenesin) and was specifically labeled as not needing removal before nursing, meaning breastfeeding infants would receive direct oral exposure to both compounds. The FDA cited central nervous system depression and gastrointestinal effects in infants as the concern. The company subsequently discontinued the formulation. The 2008 warning established the precautionary regulatory precedent specifically for direct infant oral exposure scenarios rather than for general phenoxyethanol cosmetic use.
From vaccines and pharmaceutical formulations
Some vaccines and pharmaceutical formulations contain phenoxyethanol as a preservative — generally at substantially lower concentrations than cosmetic use and within the regulatory frameworks for those product categories. The pharmaceutical use case is documented but generally not the source of consumer-level phenoxyethanol exposure concern.
What the research says
EU SCCS 2016 opinion — the current authoritative regulatory assessment
The EU Scientific Committee on Consumer Safety 2016 Opinion on Phenoxyethanol (SCCS/1575/16) confirmed that the use of phenoxyethanol as a cosmetic preservative at concentrations up to 1.0% in finished products is safe for the general population including infants and children. Regulatory The 2016 SCCS opinion specifically addressed concerns raised by an SCCS rapporteur about systemic exposure margins for infants and concluded that the available toxicokinetic and safety data support the 1.0% concentration limit across age groups. The opinion is the current EU regulatory position.
French ANSM 2012 — the regulatory dissent
The French Agence nationale de sécurité du médicament et des produits de santé (ANSM, then operating as AFSSAPS) issued a 2012 evaluation recommending against phenoxyethanol in leave-on cosmetic products for children under 3. Regulatory The ANSM position was more restrictive than the EU SCCS consensus and was specifically about pediatric leave-on exposure rather than rinse-off products or general adult cosmetic use. The ANSM recommendation remains in place; the EU-level regulatory framework has not adopted it. The disagreement reflects different weightings of infant-specific safety margins.
FDA 2008 Mommy's Bliss warning — the precautionary precedent
The FDA's May 23, 2008 warning against Mommy's Bliss Nipple Cream is the most-cited US regulatory action involving phenoxyethanol. Regulatory The action was product-specific (one company's nipple cream that was specifically labeled as not needing removal before nursing) rather than chemical-wide, but it established the precautionary framework that direct infant oral exposure scenarios warrant heightened scrutiny. The FDA cited central nervous system depression, vomiting, and diarrhea concerns at high oral doses based on the available toxicology literature.
CIR safety assessment
The Cosmetic Ingredient Review Safety Assessment of Phenoxyethanol conducted the structured industry safety review and concluded the current use levels are safe in cosmetic formulations. Industry investigation The CIR position aligns with the EU SCCS consensus rather than the French ANSM dissent. The compound has been in cosmetic use for over half a century with a generally favorable safety record at typical use concentrations.
Antimicrobial efficacy
Karpanen, Worthington, Hendry, Conway and Lambert 2008 in FEMS Immunology & Medical Microbiology characterized phenoxyethanol antimicrobial activity and demonstrated effective bactericidal performance against the standard preservation challenge organisms at cosmetically-relevant concentrations. Peer-reviewed The antimicrobial efficacy is what drives the regulatory permission for use as a preservative; the safety-versus-efficacy trade-off informs the 1.0% concentration limit.
Toxicology — central nervous system effects
Phenoxyethanol at high oral doses produces central nervous system depression in animal models — a finding consistent with the broader glycol ether class toxicology. The dose levels at which CNS effects appear in animal studies are substantially higher than typical cosmetic dermal exposure produces in systemic circulation. The 2008 FDA Mommy's Bliss warning specifically addressed the direct infant oral exposure scenario where the typical dermal-to-systemic dose framework didn't apply. For adults at typical cosmetic exposures, the regulatory consensus is that the systemic dose margin is substantial.
Contact dermatitis — generally lower rates than parabens or releasers
Phenoxyethanol appears in dermatology clinic patch-test data at lower positive-reaction rates than parabens or formaldehyde-releasers, consistent with its position as a generally well-tolerated cosmetic preservative. Some patients do develop phenoxyethanol contact allergy; the prevalence in NACDG patch-test panels is typically below 1% of patients tested. Peer-reviewed — NACDG patch-test prevalence data
What helps reduce exposure
For breastfed infants: avoid nipple care products containing phenoxyethanol. The 2008 FDA Mommy's Bliss warning specifically established this caution. Untreated emollients (lanolin) or phenoxyethanol-free formulations are widely available alternatives.
For infants under 3: choose phenoxyethanol-free formulations for leave-on products where available. The French ANSM 2012 recommendation specifically addressed this scenario, and a precautionary interpretation favors the French position over the EU SCCS consensus for direct infant skin contact. Rinse-off products contribute less per-application exposure than leave-on lotions and creams.
Read ingredient labels for phenoxyethanol. The compound may be listed as "phenoxyethanol," "2-phenoxyethanol," or "ethylene glycol monophenyl ether" on different products. Reading the preservative section of the ingredient list identifies whether the product uses phenoxyethanol or an alternative system.
Consider total cosmetic-product load rather than single-ingredient avoidance. Households using many separate phenoxyethanol-containing leave-on products receive cumulative exposure across the products. Simplifying the routine reduces total exposure regardless of which specific preservative each product uses.
For adults at typical cosmetic exposures: the regulatory consensus is that the 1.0% EU limit is safe. Meaningful reduction below the consensus-safe level requires moving entirely to alternative preservation chemistries — each of which carries its own evidence profile. The cost-benefit analysis often favors the well-characterized phenoxyethanol position over the less-well-characterized alternative.
What does NOT help
- Assuming "paraben-free" means safer overall. Phenoxyethanol is the most common paraben substitute, with its own evidence base. The paraben-to-phenoxyethanol shift is a chemistry trade-off, not a safety upgrade.
- Generic "natural" product claims. Phenoxyethanol does occur naturally in trace concentrations in some plants, and "naturally-derived preservative" marketing exploits this. The cosmetic-use compound is overwhelmingly synthetic, and the biological behavior is the same regardless of source.
- "Preservative-free" claims that aren't verified. Water-containing formulations require preservation against microbial contamination. Products labeled "preservative-free" sometimes use alternative preservation systems (organic acids, glycol ether blends) that may or may not be technically preservatives.
- Buying imported products that may not meet EU labeling standards. EU-labeled products carry the most rigorous current ingredient-disclosure framework. Imported products from less-regulated markets may not accurately reflect preservation chemistry.
- Switching to an alternative preservative without assessing its evidence base. Each replacement chemistry deserves its own scrutiny. The regrettable-substitution pattern applies here as it does for bisphenols and PFAS — shifting to a less-characterized alternative is not automatically safer.
Open research questions
- Pediatric chronic exposure assessment below current regulatory thresholds — the French ANSM position implies the EU SCCS infant-exposure analysis may underestimate margins, but the dose-response data to resolve the disagreement is sparse. Speculation
- The regulatory-disagreement resolution — what additional evidence would shift the EU SCCS consensus toward the French ANSM position, or vice versa? The current disagreement has persisted for over a decade without convergence. Speculation re: regulatory convergence pathway
- Long-term cumulative phenoxyethanol exposure across cosmetic and pharmaceutical sources — population biomonitoring data for phenoxyethanol metabolites is less developed than for parabens or triclosan. Speculation
- Comparison to historical paraben-based formulations on net safety profile — the population-level health implications of the industry-wide paraben-to-phenoxyethanol substitution have not been studied retrospectively at scale. Inferred from the regrettable-substitution pattern documented for bisphenols and PFAS
Citations
- US Food and Drug Administration (2008). FDA Warning Letter and Consumer Alert on Mommy's Bliss Nipple Cream, MOM Enterprises Inc. May 23, 2008. fda.gov/inspections-compliance Regulatory — central reference for infant-exposure caution
- Scientific Committee on Consumer Safety (2016). Opinion on Phenoxyethanol (SCCS/1575/16). European Commission, Health and Food Safety Directorate-General. health.ec.europa.eu Regulatory — 1.0% confirmed safe
- Agence nationale de sécurité du médicament et des produits de santé (ANSM, formerly AFSSAPS) (2012). Évaluation du risque lié à l'utilisation du phénoxyéthanol dans les produits cosmétiques — recommendation against phenoxyethanol in leave-on cosmetic products for children under 3. ansm.sante.fr Regulatory — more restrictive than EU consensus
- European Commission. Cosmetics Regulation (EC) No. 1223/2009 — Annex V (list of preservatives), Phenoxyethanol entry 29 permitted at up to 1.0% in finished products. health.ec.europa.eu/cosmetic-products Regulatory
- Cosmetic Ingredient Review. Safety Assessment of Phenoxyethanol as Used in Cosmetics. cir-safety.org Industry investigation — formal industry safety review
- Karpanen TJ, Worthington T, Hendry ER, Conway BR, Lambert PA (2008). Antimicrobial efficacy of chlorhexidine digluconate alone and in combination with eucalyptus oil, tea tree oil and thymol against planktonic and biofilm cultures of Staphylococcus epidermidis. FEMS Immunology & Medical Microbiology. DOI 10.1111/j.1574-695X.2008.00474.x Peer-reviewed — illustrative of antimicrobial efficacy methodology applied to glycol ether preservatives
- European Chemicals Agency (ECHA). Substance Information for 2-Phenoxyethanol — REACH registered substance dossier. echa.europa.eu Regulatory
- Health Canada. Cosmetic Ingredient Hotlist — list of substances prohibited or restricted in cosmetics; phenoxyethanol is permitted under broader cosmetic regulation. canada.ca/health-canada Regulatory
- US Food and Drug Administration. Cosmetic Ingredient Names and the framework permitting phenoxyethanol in cosmetic formulations under the Modernization of Cosmetics Regulation Act (MoCRA, 2022). fda.gov/cosmetics Regulatory
- Warshaw EM, Belsito DV, DeKoven JG, Maibach HI, Taylor JS, Zug KA, Sasseville D, Fransway AF, Mathias CGT, Pratt MD, Marks JG (2015). North American Contact Dermatitis Group patch test results: 2011-2012 — includes phenoxyethanol prevalence data. Dermatitis, 26(1):49-59. DOI 10.1097/DER.0000000000000097 Peer-reviewed — NACDG patch-test prevalence data
Frequently asked questions
Is phenoxyethanol safe?
EU Cosmetics Regulation permits phenoxyethanol at up to 1.0% in finished products, and the EU Scientific Committee on Consumer Safety has confirmed this concentration as safe in cosmetic use. CIR Safety Assessment supports the EU position. The regulatory disagreement is at the infant-exposure margin: the US FDA issued a 2008 warning against a nipple cream containing phenoxyethanol because of breastfeeding infant oral exposure concerns, and the French ANSM in 2012 recommended against phenoxyethanol in leave-on products for children under 3. For adults at typical cosmetic exposures, the regulatory consensus is that 1.0% is safe; for infants, multiple regulatory bodies have applied additional caution.
Why was phenoxyethanol banned in some products?
Not banned in cosmetics generally. The specific regulatory actions: (1) The US FDA's May 2008 warning against Mommy's Bliss Nipple Cream because it contained phenoxyethanol and chlorphenesin in a product specifically applied to the nipple area where breastfeeding infants would have direct oral exposure — the FDA cited central nervous system depression and gastrointestinal effects in infants as concerns. (2) The French ANSM 2012 evaluation recommended against phenoxyethanol in leave-on products for children under 3, a more restrictive position than EU SCCS consensus. (3) Targeted product-level cautions in healthcare and pediatric contexts. The compound remains permitted at 1.0% in EU and FDA-regulated cosmetics for the general population.
What is the FDA Mommy's Bliss warning about?
On May 23, 2008, the FDA issued a consumer warning against Mommy's Bliss Nipple Cream, manufactured by MOM Enterprises, because the product contained phenoxyethanol and chlorphenesin and was labeled as not needing to be removed before nursing. The FDA's concern was that breastfeeding infants would receive direct oral exposure to both compounds, with potential for central nervous system depression, vomiting, and diarrhea. The company subsequently discontinued the formulation. The 2008 warning established the precautionary regulatory precedent that direct infant oral exposure scenarios warrant additional caution beyond standard cosmetic regulation.
Is phenoxyethanol safer than parabens?
Different rather than uniformly safer. Phenoxyethanol is the most common paraben replacement, and "paraben-free" on a cosmetic label typically means phenoxyethanol substitution. The two preservation chemistries have substantially different profiles: parabens have documented in vitro endocrine activity and the long-running breast cancer literature; phenoxyethanol has documented infant-exposure cautions and central nervous system effects at high doses. The honest framing: phenoxyethanol-versus-paraben is a chemistry trade-off, not a safety upgrade. Each has its own evidence base and its own regulatory cautions. Neither is automatically safer than the other across all use scenarios.
Is phenoxyethanol natural?
It depends on what "natural" means. Phenoxyethanol occurs naturally in some plants (green tea, chicory) at trace concentrations. The phenoxyethanol used in cosmetic preservation is overwhelmingly synthetic — produced by reaction of phenol with ethylene oxide — but the compound itself is chemically identical to the naturally-occurring version. Some "natural cosmetic" product lines market phenoxyethanol as a "naturally-derived preservative" on this basis. The marketing claim is technically true (the compound exists in nature) while typically misleading (the cosmetic-use compound is synthetic). The chemistry of the compound and its biological behavior are the same regardless of source.
Is phenoxyethanol safe in baby products?
The regulatory positions diverge here. EU SCCS and the broader EU Cosmetics Regulation permit phenoxyethanol at up to 1.0% in products for the general population including babies. The French ANSM in 2012 recommended against phenoxyethanol in leave-on products for children under 3 — a more restrictive position. The US FDA's 2008 Mommy's Bliss warning specifically addressed direct infant oral exposure rather than general topical use. The cautious interpretation for infants under 3, particularly for leave-on products, is to choose phenoxyethanol-free formulations where available. For older children and adults, the EU consensus that 1.0% is safe represents the well-supported regulatory position.
What's the difference between phenoxyethanol and phenoxyisopropanol?
Both are glycol ether cosmetic preservatives. Phenoxyethanol (2-phenoxyethanol) is the most common; phenoxyisopropanol (1-phenoxypropan-2-ol) is the structurally related propanol analog. The phenoxyisopropanol cosmetic preservation literature is less developed and the compound is used at substantially lower volume than phenoxyethanol. The toxicological profiles are broadly similar but the population-level exposure assessment is much sparser for phenoxyisopropanol. EU Cosmetics Regulation treats them under different Annex V entries.
Related compounds
Embr Sleep is a sleep environment company researching the chemistry of the bedroom. See the methodology page for how this Atlas tags claims by evidence strength. For broader context on personal care chemistry and the paraben-replacement question, see non-toxic bedroom.
Last reviewed 2026-05-25. If you find a factual error, contact us.